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Abstract 
Objectives. To evaluate plasma mitochondrial DNA (mtDNA) levels among HIV-infected patients and its potential 
role as a biomarker of residual viral replication. 
Methods. HIV-infected patients on follow-up at a reference hospital in north-west Spain were selected. DNA was 
isolated from plasma samples and mtDNA levels were assessed using a quantitative real-time PCR assay. HIV-RNA 
levels and CD4+ cell counts were evaluated in the same blood samples used for plasma mtDNA quantification. 
Epidemiological and clinical variables were included for the analysis. 
Results. A total of 235 HIV-infected patients were included. Mean plasma mtDNA levels were 217 ± 656 copies/μL 
for naive (31.9%) and 364 ± 939 copies/μL for HIV-infected patients receiving ART and with suppressed viraemia 
(P = 0.043). Among the latter, mean plasma mtDNA levels were 149 ± 440 copies/μL for those with low-level 
viraemia (LLV; HIV-RNA 20–200 copies/mL), 265 ± 723 copies/μL for those with detected-not-quantified (DNQ) 
viraemia (HIV-RNA <20 copies/mL) and 644 ± 1310 copies/μL for those with not-detected (ND) viraemia. Of note, a 
linear trend (P = 0.006) was observed among virologically suppressed (LLV, DNQ and ND) patients. ND patients had 
higher mtDNA levels compared with LLV patients (P = 0.057). Moreover, mtDNA levels were inversely associated 
with HIV-RNA levels (Spearman’s rho −0.191, P = 0.003) and directly associated with CD4+ counts (Spearman’s 
rho 0.131, P = 0.046). 
Conclusions. Increased plasma mtDNA levels are associated with lower HIV-RNA levels and higher CD4+ cell 
counts. Among ART-suppressed patients, mtDNA levels were significantly higher in those with complete virological 
suppression (ND) than in those with LLV. These data suggest that plasma mtDNA levels might serve as a biomarker 
of residual HIV replication. 
Topic: hiv, biological markers, cd4 count determination procedure, dna, mitochondrial, plasma, viremia, virus 
replication, virology, blood hiv rna, hiv infection  
 
 
 
 
  
Introduction 
Current ART combinations effectively suppress HIV replication for extended periods of time and 
reduce the degree of immune dysfunction. However, the effect of ART seems to be limited in terms of 
activation, and a chronic inflammatory state persists in most patients on ART, which has been related 
with poor clinical outcomes, including development of AIDS and non-AIDS defining events and death.
1,2
 
It remains to be elucidated whether residual viral replication occurring despite ART fuels immune 
activation and chronic inflammation. 
 
Mitochondria are intracellular organelles involved in a wide range of processes, as they are the main 
source of cellular energy.
3
 Their number and shape constantly change in response to energy demands. In 
fact, mitochondrial dysfunction has been implicated in ageing and pathological processes, such as 
carcinogenesis and inflammation.
4,5
 This fact implies a possible role of mitochondrial DNA (mtDNA) as 
a potential biomarker in processes associated with oxidative stress and inflammation. Several studies have 
described that the metabolic stress derived from HIV replication may result in mitochondrial damage and 
mtDNA depletion.
6–11 
 
In this context, the aim of this study was to evaluate the correlation between mtDNA and HIV-RNA 
levels in HIV-infected patients and to investigate whether mtDNA might be used as a biomarker of 
residual viral replication among patients on ART resulting in viral suppression. 
Materials and methods 
Quantification of plasma mtDNA levels was performed in blood samples obtained from an 
observational cohort of HIV-infected patients in clinical follow-up at Complexo Hospitalario 
Universitario de A Coruña. Epidemiological and ART characteristics were retrospectively recorded. In 
addition, HIV-RNA levels (determined using Roche COBAS TaqMan test version 2.0 with a limit of 
detection of 20 copies/mL) and CD4+ cell counts were assessed in the same blood samples used for 
plasma mtDNA quantification. 
 
Whole-plasma DNA was isolated from plasma using a DNAeasy Blood and Tissue kit (Qiagen). 
Briefly, 400 μL of PBS was added to 400 μL of plasma samples and then centrifuged at 16000 g for 
15 min at 4 °C. Then, 200 μL of supernatant was subsequently processed according to the manufacturer’s 
protocol, and finally 100 μL of elution buffer was added to resolve the isolated plasma DNA. 
 
Plasma mtDNA levels were measured in duplicate by SYBR Green dye-based quantitative real-time 
PCR assay using a LightCycler II (Roche) thermal cycler. The primer sequences were human 12S 
ribosomal RNA (mtDNA): forward sequence CCACGGGAAACAGCAGTGAT; reverse sequence 
CTATTGACTTGGGTTAATCGTGTGA. Total DNA obtained from an immortalized cell line was 
diluted in 10-fold serial dilutions and used as standard curve. Plasma mtDNA levels were shown in copies 
of plasma according to the following formula:
12C = Q × VDNA/VPCR × 1/Vext, where C is the concentration 
of plasma mtDNA (copies/μL), Q is the quantity of DNA measured by real-time PCR, VDNA is the total 
volume of plasma DNA solution obtained from the extraction (100 μL in this study), VPCR is the volume 
of plasma DNA solution for real-time PCR (5 μL in this study) and Vext is the volume of plasma used for 
the extraction (400 μL in this study). 
 
The reaction mix consisted of 10 μL of SYBR Green ready reaction mix (Roche®), 0.3 μM forward 
and reverse primers, 5 μL of plasma DNA and up to 20 μL of double-distilled water. The thermal cycler 
programme consisted of a first activation cycle at 95 °C for 10 min, followed by an amplification 
programme of 45 cycles (95 °C for 10 s, 62 °C for 60 s and 72 °C for 5 s). In order to verify the 
amplification products, a melting cycle was additionally performed (95 °C for 5 s and 65 °C for 60 s, 
followed by a gradual temperature increase up to 97 °C). Finally, the mix was cooled at 40 °C for 20 s. 
 
Statistical analysis was performed using the Statistical Package for the Social Sciences software 
(SPSS 19.0, Chicago, IL, USA). Continuous variables were compared by non-parametric Mann–Whitney 
and Kruskal–Wallis tests, as appropriate. Correlations between mtDNA levels and HIV-related 
parameters were determined using Spearman’s correlation analysis. Polynomial contrasts were used to 
evaluate linear trends between mtDNA levels and groups of HIV-infected patients receiving ART 
resulting in virological suppression. A P value <0.05 was considered statistically significant.  
Results 
A total of 235 HIV-infected patients were included. Of these, 83.3% were male, and their mean age 
was 44.6 ± 11 years. Main routes of HIV transmission were: MSM (43%), heterosexual (33%) and 
intravenous drug users (23.5%). CD4 nadir was <200 cells/mm3 in 40.7% of patients, and 15.3% had an 
AIDS-defining disease. 
 
Overall, 31.9% were naive (mean HIV-RNA 4.64 ± 0.64 log10 copies/mL) while the remainder were 
receiving ART: 24.3% had not-detected (ND) HIV-RNA, 23% had <20 copies/mL and detected-not-
quantified (DNQ) HIV-RNA and 20.9% had low-level viraemia (LLV) with 20–200 copies/mL of HIV-
RNA. 
 
Mean plasma mtDNA levels were 217 ± 656 copies/μL for naive patients and 364 ± 939 copies/μL for 
HIV-infected patients receiving ART (P = 0.043) (Figure 1). According to HIV-RNA quantification 
among the whole population, mean plasma mtDNA levels were 364 ± 939 copies/μL for patients with 
HIV-RNA <3 log10 copies/mL; 273 ± 752 copies/μL for 3–5 log10 copies/mL; and 51 ± 45 copies/μL for 
HIV-RNA >5 log10 copies/mL. Of note, mtDNA levels were inversely associated with HIV-RNA levels 
(Spearman’s rho −0.191, P = 0.003) among the whole population (Figure 2). 
 
 
 
Figure 1. Comparison of mtDNA levels expressed as mean (95% CI) among HIV patients. (a) Naive versus HIV-infected patients 
with virological suppression (HIV-RNA <200 copies/mL) receiving ART. (b) HIV-infected patients with ND viraemia, DNQ 
viraemia (HIV-RNA <20 copies/mL) and LLV (20–200 copies/mL) receiving ART. 
  
 
 
 
Figure 2. Correlation between HIV-RNA (copies/mL) (a) or CD4 count (cells/mm3) (b) and mitochondrial DNA (mtDNA) levels 
(copies/μL) according to Spearman’s rho analysis among the whole population. 
In addition, mean plasma mtDNA levels were 149 ± 440 copies/μL for those with LLV, 
265 ± 723 copies/μL for DNQ viraemia and 644 ± 1310 copies/μL for those with ND viraemia. 
Interestingly, among patients receiving ART, those with LLV had lower levels of mtDNA than those with 
ND viraemia (P = 0.057). Although no differences in mtDNA levels were observed between ND and 
DNQ patients, the trend analysis showed that mtDNA levels decrease among virologically suppressed 
HIV-infected patients (ND, DNQ and LLV) in a linear way (Figure 1). The F-ratio for the linear trend 
was 7.81 (P = 0.006). In addition, significant differences were observed between naive and patients 
receiving ART with ND viraemia (217 ± 656 versus 643 ± 1310 copies/μL, P = 0.010). Among HIV-
infected patients receiving ART, no differences in plasma mtDNA levels were observed according to the 
different ART regimens used (NNRTI-, PI- or integrase inhibitor-based combinations) (P = 0.808). 
 
In regard to the immunological status, mean mtDNA levels were directly associated with CD4+ cell 
counts among the whole population: ≤200 cells/mm3, 60 ± 64 copies/μL; 201–350 cells/mm3, 
270 ± 803 copies/μL; 351–500 cells/mm3, 278 ± 622 copies/μL and >500 cells/mm3, 
417 + 1075 copies/μL, respectively (Spearman’s rho 0.131, P = 0.046) (Figure 2). 
 
Moreover, a negative correlation between mtDNA levels and HIV-RNA (Spearman’s rho −0.246, 
P = 0.011) was found for the subgroup of patients with CD4+ cell count >500 cells/mm3, and a positive 
correlation between mtDNA levels and CD4+ cell count (Spearman’s rho 0.296, P = 0.028) was also 
found for the subgroup of ND viraemia. Interestingly, multivariate lineal regression found a linear 
regression coefficient of 0.636 for CD4+ cell count (P = 0.010) and −4.171 for HIV-RNA levels 
(P = 0.043) among virologically suppressed HIV-infected patients receiving ART. 
  
Discussion 
This study evaluated the potential role of plasma mtDNA levels as a biomarker of residual viral 
replication. Of 235 HIV-infected patients, 31.9% were naive and the rest of patients were receiving ART 
with different levels of HIV-RNA quantification. Herein, to our knowledge, we provide the first clinical 
evidence that mtDNA levels showed a linear trend among virologically suppressed HIV-infected patients 
receiving ART. In fact, those patients with complete virological suppression (HIV-RNA ND) have a trend 
towards higher mtDNA levels than HIV-infected patients with LLV (20–200 copies/mL) receiving ART. 
Of note, increased plasma mtDNA levels were associated with lower HIV-RNA levels and higher CD4+ 
cell counts. 
 
These data suggest that plasma mtDNA levels could be a biomarker of residual viral replication 
beyond HIV-RNA quantification associated with mitochondrial damage, as a consequence of an 
inadequate control of HIV replication. 
 
Likewise, some studies have shown mtDNA depletion in HIV-infected patients compared with HIV-
negative controls.
6–11
 Different results were found in other studies, likely due to the heterogeneity of the 
study populations and/or the methodology used. For example, no impact on mtDNA levels has been 
described among untreated HIV-infected patients, elite controllers, ART-suppressed or HIV-negative 
subjects.
1
 However, higher mtDNA plasma levels have been described in acute HIV infection and late 
presenters compared with long-term non-progressors and healthy individuals.
13
 Correlation of 
mitochondrial toxicity with CD4 counts or HIV-RNA levels was not reported from previous studies 
conducted in HIV-infected patients.
6–11
 As an exception, Miura et al.
14
 found that mtDNA levels were 
positively correlated with CD4+ cell counts and inversely correlated with plasma HIV-RNA in naive 
patients. Similarly, this study showed a positive correlation between mtDNA levels and CD4+ cell 
counts, while a negative correlation was found with HIV-RNA levels. The mechanisms underlying these 
findings are not yet elucidated and different viral and host factors might be influencing mitochondrial 
function. Based on the results obtained, we speculate that among treatment-naive patients, continuous 
antigenic exposure might lead to T cell exhaustion and a decrease in mitochondrial biogenesis. 
Conversely, low levels of ongoing HIV replication and ultimately the complete suppression of HIV-1 
replication by ART might restore T cell proliferation and mitochondrial biogenesis.
15
 Our data also 
suggest that even in the context of LLV replication or DNQ viraemia, persistent antigen exposure might 
still have a negative effect on the mitochondria, although lower than in the naive population. Moreover, 
this explanation would fit with the positive correlation found between mtDNA levels and CD4+ cell 
count. 
 
Nowadays, most HIV-infected patients receiving ART exhibit suppressed viraemia for long periods of 
time. Although LLV is frequently detected in these patients, its clinical impact is far from clear. We have 
recently described an association of persistent residual viraemia (at least three consecutive determinations 
of HIV-RNA <20 copies/mL and DNQ) with virological failure.16 However, HIV treatment guidelines 
consider that transient LLV has no clinical relevance. Indeed, the Department of Health and Human 
Services guidelines consider virological failure as HIV-RNA >200 copies/mL.17 Interestingly, we found 
that lower levels of mtDNA were observed in patients with LLV (HIV-RNA 20–200 copies/mL) 
compared with HIV-infected patients with ND viraemia. Although no significant differences were 
observed between ND and DNQ patients, a linear trend was found according to the level of viraemia 
among suppressed patients receiving ART (LLV, DNQ and ND). 
 
It is tempting to speculate that HIV-1 infection itself may be responsible for a decrease in mtDNA 
although the mechanisms underlying this conjecture need to be established. In the context of HIV 
replication even at low levels, chronic antigen exposure might impair mitochondria biogenesis. In this 
context, mitochondrial metabolism might be reprogramming toward fatty acid oxidation, increasing the 
generation of reactive oxygen species that might further affect mtDNA integrity as has been described in 
the context of viral infections.
15,18
 In addition, certain HIV proteins, such as Vpr, have been shown to 
adversely affect mitochondrial integrity.
19 
 
This study has some limitations. Comparisons with an HIV- negative population were not made. 
However, a large number of HIV-infected patients with different HIV-RNA levels were included, 
allowing a detailed evaluation regarding the impact of HIV replication on mtDNA levels. On the other 
hand, the techniques used to measure mtDNA levels are not standardized among published studies. This 
fact might explain differences in the results found in the literature.  
In conclusion, our results are consistent with the concept that HIV replication may be associated with 
mtDNA depletion. Among patients receiving ART, higher mtDNA levels were found in patients with ND 
viraemia compared with those with LLV and DNQ, suggesting a potential role of mtDNA level as a 
biomarker of residual viral replication. Therefore, mtDNA level might be considered as a surrogate 
marker in studies addressing viral eradication. 
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